vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Iridium Communications Inc. (IRDM). Click either name above to swap in a different company.
Iridium Communications Inc. is the larger business by last-quarter revenue ($219.1M vs $183.1M, roughly 1.2× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 9.9%, a 3.5% gap on every dollar of revenue. On growth, Iridium Communications Inc. posted the faster year-over-year revenue change (1.9% vs -1.8%). Over the past eight quarters, Iridium Communications Inc.'s revenue compounded faster (4.4% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Iridium Communications Inc. is a publicly traded American company headquartered in McLean, Virginia, United States. Iridium operates the Iridium satellite constellation, a system of 80 satellites: 66 are active satellites and the remaining fourteen function as in-orbit spares. Iridium Satellites are used for worldwide voice and data communication from handheld satellite phones, satellite messenger communication devices and integrated transceivers, as well as for two-way satellite messaging se...
AMPH vs IRDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $219.1M |
| Net Profit | $24.4M | $21.6M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 23.2% |
| Net Margin | 13.3% | 9.9% |
| Revenue YoY | -1.8% | 1.9% |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $219.1M | ||
| Q4 25 | $183.1M | $212.9M | ||
| Q3 25 | $191.8M | $226.9M | ||
| Q2 25 | $174.4M | $216.9M | ||
| Q1 25 | $170.5M | $214.9M | ||
| Q4 24 | $186.5M | $213.0M | ||
| Q3 24 | $191.2M | $212.8M | ||
| Q2 24 | $182.4M | $201.1M |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $24.4M | $24.9M | ||
| Q3 25 | $17.4M | $37.1M | ||
| Q2 25 | $31.0M | $22.0M | ||
| Q1 25 | $25.3M | $30.4M | ||
| Q4 24 | $38.0M | $36.3M | ||
| Q3 24 | $40.4M | $24.4M | ||
| Q2 24 | $37.9M | $32.3M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | 23.2% | ||
| Q4 25 | 19.4% | 25.9% | ||
| Q3 25 | 13.2% | 30.9% | ||
| Q2 25 | 24.2% | 23.2% | ||
| Q1 25 | 21.9% | 28.1% | ||
| Q4 24 | 24.2% | 24.5% | ||
| Q3 24 | 29.8% | 25.8% | ||
| Q2 24 | 30.3% | 21.7% |
| Q1 26 | — | 9.9% | ||
| Q4 25 | 13.3% | 11.7% | ||
| Q3 25 | 9.0% | 16.4% | ||
| Q2 25 | 17.8% | 10.1% | ||
| Q1 25 | 14.8% | 14.2% | ||
| Q4 24 | 20.4% | 17.1% | ||
| Q3 24 | 21.1% | 11.5% | ||
| Q2 24 | 20.8% | 16.1% |
| Q1 26 | — | — | ||
| Q4 25 | $0.51 | $0.24 | ||
| Q3 25 | $0.37 | $0.35 | ||
| Q2 25 | $0.64 | $0.20 | ||
| Q1 25 | $0.51 | $0.27 | ||
| Q4 24 | $0.74 | $0.30 | ||
| Q3 24 | $0.78 | $0.21 | ||
| Q2 24 | $0.73 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | — |
| Total Assets | $1.6B | — |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | $96.5M | ||
| Q3 25 | $276.2M | $88.5M | ||
| Q2 25 | $231.8M | $79.3M | ||
| Q1 25 | $236.9M | $50.9M | ||
| Q4 24 | $221.6M | $93.5M | ||
| Q3 24 | $250.5M | $159.6M | ||
| Q2 24 | $217.8M | $63.5M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | $1.8B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $1.8B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | — | ||
| Q4 25 | $788.8M | $462.6M | ||
| Q3 25 | $776.7M | $450.5M | ||
| Q2 25 | $757.5M | $473.6M | ||
| Q1 25 | $751.3M | $518.4M | ||
| Q4 24 | $732.3M | $576.6M | ||
| Q3 24 | $727.7M | $663.8M | ||
| Q2 24 | $713.3M | $786.7M |
| Q1 26 | — | — | ||
| Q4 25 | $1.6B | $2.5B | ||
| Q3 25 | $1.7B | $2.6B | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.5B | $2.8B | ||
| Q2 24 | $1.5B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | 3.80× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 3.05× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | 13.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $108.6M | ||
| Q3 25 | $52.6M | $100.8M | ||
| Q2 25 | $35.6M | $129.6M | ||
| Q1 25 | $35.1M | $61.1M | ||
| Q4 24 | $29.0M | $104.8M | ||
| Q3 24 | $60.0M | $118.6M | ||
| Q2 24 | $69.1M | $81.1M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $75.1M | ||
| Q3 25 | $47.2M | $79.2M | ||
| Q2 25 | $25.0M | $108.9M | ||
| Q1 25 | $24.4M | $36.5M | ||
| Q4 24 | $16.6M | $80.5M | ||
| Q3 24 | $46.2M | $100.0M | ||
| Q2 24 | $63.1M | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 35.3% | ||
| Q3 25 | 24.6% | 34.9% | ||
| Q2 25 | 14.3% | 50.2% | ||
| Q1 25 | 14.3% | 17.0% | ||
| Q4 24 | 8.9% | 37.8% | ||
| Q3 24 | 24.1% | 47.0% | ||
| Q2 24 | 34.6% | 34.2% |
| Q1 26 | — | 13.7% | ||
| Q4 25 | 4.5% | 15.7% | ||
| Q3 25 | 2.8% | 9.5% | ||
| Q2 25 | 6.1% | 9.5% | ||
| Q1 25 | 6.3% | 11.4% | ||
| Q4 24 | 6.7% | 11.4% | ||
| Q3 24 | 7.2% | 8.7% | ||
| Q2 24 | 3.3% | 6.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 4.37× | ||
| Q3 25 | 3.03× | 2.71× | ||
| Q2 25 | 1.15× | 5.90× | ||
| Q1 25 | 1.39× | 2.01× | ||
| Q4 24 | 0.76× | 2.88× | ||
| Q3 24 | 1.48× | 4.85× | ||
| Q2 24 | 1.82× | 2.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
IRDM
| Voice and data | $57.4M | 26% |
| IoT data (2) | $46.0M | 21% |
| Government | $39.5M | 18% |
| Government service revenue (5) | $27.6M | 13% |
| Subscriber equipment | $20.2M | 9% |
| Hosted payload and other data service (4) | $14.8M | 7% |
| Broadband (3) | $12.2M | 6% |
| Commercial | $1.3M | 1% |
